Grape King Bio : Announcement of the Company's Consolidated Financial Report for the second quarter of 2022 has been approved by the Board of Directors
Announcement of the Company's Consolidated
Financial Report for the second quarter of 2022 has been
approved by the Board of Directors
Date of events
2022/08/10
To which item it meets
paragraph 31
Statement
1.Date of submission to the board of directors or approval by the board of
directors:2022/08/10
2.Date of approval by the audit committee:2022/08/10
3.Start and end dates of financial reports or annual self-assessed financial
information of the reporting period (XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):4,775,053
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):3,919,655
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):1,090,238
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):1,149,356
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):930,807
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):620,718
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):4.19
11.Total assets end of the period (thousand NTD):14,545,490
12.Total liabilities end of the period
(thousand NTD):4,646,283
13.Equity attributable to owners of parent end of the
period (thousand NTD):8,730,774
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Grape King Bio Ltd. published this content on 10 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 August 2022 08:36:03 UTC.
Grape King Bio Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of healthcare products and beverages. The company operates through three business segments. The Direct Sales segment is engaged in the development and manufacture of related products for subsidiaries. The Distribution segment is engaged in the provision of own-brand products. The Original Equipment Manufacturer (OEM) segment is engaged in the OEM business in Taiwan and Shanghai. The main products include lactic acid bacteria products and other healthcare products, as well as beverage products, medicines and cosmetics. The Company operates in Taiwan, mainland China and other markets.
Grape King Bio : Announcement of the Company's Consolidated Financial Report for the second quarter of 2022 has been approved by the Board of Directors